Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of switching biologic treatment in moderate to severe plaque psoriasis
ChiCTR2400092920Phase 4Not yet recruiting
- Sponsor
- Affiliated Suzhou Hospital of Nanjing Medical University
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ustekinumab, guselkumab, tildrakizumab, secukinumab, ixekizumab and 5 more in plaque psoriasis (6 cohorts), sponsored by Affiliated Suzhou Hospital of Nanjing Medical University. Primary endpoint: Physician's Global Assessment. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
ustekinumabguselkumabtildrakizumabsecukinumabixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2400092920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092920.